DPDaniel Pabón-Carrasco

Daniel Pabón-Carrasco

*This is an algorithmically generated author record based on publicly available information.

Daniel Pabón-Carrasco has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Influence of Ultra-Processed Food on Colorectal Cancer: A Systematic Review

    by Rocío Caceres-Matos, Aurora Castro-Méndez, Marina García Domínguez, Daniel Pabón-Carrasco, Manuel Pabón-Carrasco

    Colorectal cancer (CRC) is a disease characterised by the development of malignant tumours in the colon or rectum; it is considered the most common cancer in women, and up to 50% of cases can be prevented with a healthy lifestyle. Nutritional habits are related to its appearance, and the current trend of an increased consumption of ultra-processed foods (UPFs) has led to a surge in the incidence of CRC in recent years. This systematic review aims to evaluate, based on scientific evidence, the role of UPF in the incidence of CRC. The PubMed, Scopus, CINAHL, and Web of Science databases were reviewed, and a total of 24 scientific articles were selected according to the inclusion and exclusion criteria of this review (studies from the past 5 years and observational studies in English). The conclusions of this study point to an association between UPF-based diets and the appearance of CRC, which is promoted by the harmful effects of the consumption of high levels of sugar, fat, red meat, and additives. These dietary habits, coupled with a sedentary lifestyle and obesity, further increase the incidence of CRC.


  • Open Access

    Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis

    by Manuel Pabón-Carrasco, Rocio Caceres-Matos, Marta Roche-Campos, Maria Antonia Hurtado-Guapo, Mercedes Ortiz-Romero, Luis M. Gordillo-Fernández, Daniel Pabón-Carrasco, Aurora Castro-Méndez

    Epidermolysis bullosa (EB) is the overarching term for a set of rare inherited skin fragility disorders that result from mutations in at least 20 different genes. Currently, there is no cure for any of the EB subtypes associated with various mutations. Existing therapies primarily focus on alleviating pain and promoting early wound healing to prevent potential complications. Consequently, there is an urgent need for innovative therapeutic approaches. The objective of this research was to assess the efficacy of various topical treatments in patients with EB with the goal of achieving wound healing. A secondary objective was to analyse the efficacy of topical treatments for symptom reduction. A literature search was conducted using scientific databases, including The Cochrane Library, Medline (Pubmed), Web of Science, CINHAL, Embase, and Scopus. The protocol review was registered in PROSPERO (ID: 418790), and inclusion and exclusion criteria were applied, resulting in the selection of 23 articles. Enhanced healing times were observed compared with the control group. No conclusive data have been observed on pain management, infection, pruritus episodes, and cure rates over time. Additionally, evidence indicates significant progress in gene therapies (B-VEC), as well as cell and protein therapies. The dressing group, Oleogel S-10, allantoin and diacerein 1%, were the most represented, followed by fibroblast utilisation. In addition, emerging treatments that improve the patient’s innate immunity, such as calcipotriol, are gaining attention. However, more trials are needed to reduce the prevalence of blistering and improve the quality of life of individuals with epidermolysis bullosa.